Wealthfront Advisers LLC bought a new stake in shares of Sanofi (NASDAQ:SNY – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 39,551 shares of the company’s stock, valued at approximately $1,908,000.
A number of other large investors also recently modified their holdings of SNY. Synergy Asset Management LLC purchased a new stake in Sanofi in the 4th quarter worth $25,000. McClarren Financial Advisors Inc. lifted its stake in Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares in the last quarter. Sunbelt Securities Inc. lifted its stake in Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares in the last quarter. Sierra Ocean LLC purchased a new stake in Sanofi in the 4th quarter worth $44,000. Finally, Versant Capital Management Inc purchased a new stake in Sanofi in the 4th quarter worth $54,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.
Analyst Ratings Changes
Several analysts have commented on the stock. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Sanofi presently has a consensus rating of “Buy” and a consensus price target of $60.00.
Sanofi Price Performance
Shares of NASDAQ SNY opened at $57.75 on Friday. The firm’s 50-day moving average price is $53.65 and its 200-day moving average price is $52.86. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $146.56 billion, a price-to-earnings ratio of 23.19, a P/E/G ratio of 1.01 and a beta of 0.58. Sanofi has a 12-month low of $45.22 and a 12-month high of $60.12.
Sanofi (NASDAQ:SNY – Get Free Report) last announced its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, equities research analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
See Also
- Five stocks we like better than Sanofi
- Insider Trading – What You Need to Know
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- What is a buyback in stocks? A comprehensive guide for investors
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- The Risks of Owning Bonds
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.